drugset / Trial / NCT05160896
SALIRI Based Regimen as First-line Treatment for Advanced Metastatic Colorectal Cancer
NaSingle-groupOpen-labelTreatment
Summary
The objective is to investigate the efficacy and safety of raltitrexed combined with Irinotecan (SALIRI) based regimen as first-line treatment for advanced metastatic colorectal cancer(mCRC).
Timeline
- Start
- 2021-11-12
- Primary completion
- 2023-06-30
- Completion
- 2023-06-30
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Bevacizumab | Monoclonal antibody | 5 mg/kg | Intravenous |
| Subject | Cetuximab | Monoclonal antibody | 500 mg/m2 | Intravenous |
| Subject | Irinotecan | Small molecule | 180 mg/m2 | Intravenous |
| Subject | Raltitrexed | Small molecule | 2 mg/m2 | Intravenous |